You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameLercanidipine
Accession NumberDB00528  (APRD00193)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionLercanidipine is a calcium channel blocker of the dihydropyridine class. It is sold under various commercial names including Zanidip.
Structure
Thumb
Synonyms
Lercanidipine
Lercanil
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIV7XTJ4R0BH
CAS number100427-26-7
WeightAverage: 611.7272
Monoisotopic: 611.299536059
Chemical FormulaC36H41N3O6
InChI KeyZDXUKAKRHYTAKV-UHFFFAOYSA-N
InChI
InChI=1S/C36H41N3O6/c1-24-31(34(40)44-6)33(28-18-13-19-29(22-28)39(42)43)32(25(2)37-24)35(41)45-36(3,4)23-38(5)21-20-30(26-14-9-7-10-15-26)27-16-11-8-12-17-27/h7-19,22,30,33,37H,20-21,23H2,1-6H3
IUPAC Name
3-{1-[(3,3-diphenylpropyl)(methyl)amino]-2-methylpropan-2-yl} 5-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
SMILES
COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)(C)CN(C)CCC(C1=CC=CC=C1)C1=CC=CC=C1
Pharmacology
IndicationFor the treatment of Hypertension, management of angina pectoris and Raynaud's syndrome
Structured Indications Not Available
PharmacodynamicsLercanidipine, a dihydropyridine calcium-channel blocker, is used alone or with an angiotensin-converting enzyme inhibitor, to treat hypertension, chronic stable angina pectoris, and Prinzmetal's variant angina. Lercanidipine is similar to other peripheral vasodilators. Lercanidipine inhibits the influx of extra cellular calcium across the myocardial and vascular smooth muscle cell membranes possibly by deforming the channel, inhibiting ion-control gating mechanisms, and/or interfering with the release of calcium from the sarcoplasmic reticulum. The decrease in intracellular calcium inhibits the contractile processes of the myocardial smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload.
Mechanism of actionBy deforming the channel, inhibiting ion-control gating mechanisms, and/or interfering with the release of calcium from the sarcoplasmic reticulum, Lercanidipine inhibits the influx of extracellular calcium across the myocardial and vascular smooth muscle cell membranes The decrease in intracellular calcium inhibits the contractile processes of the myocardial smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload.
TargetKindPharmacological actionActionsOrganismUniProt ID
Voltage-dependent calcium channel gamma-1 subunitProteinyes
inhibitor
HumanQ06432 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
2-HYDROXY-1,4-NAPHTHOQUINONEThe risk or severity of adverse effects can be increased when 2-HYDROXY-1,4-NAPHTHOQUINONE is combined with Lercanidipine.Experimental
2-mercaptobenzothiazoleThe risk or severity of adverse effects can be increased when 2-mercaptobenzothiazole is combined with Lercanidipine.Vet Approved
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Lercanidipine.Experimental
AcebutololLercanidipine may increase the hypotensive activities of Acebutolol.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Acetazolamide.Approved, Vet Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Lercanidipine.Approved
AlfuzosinAlfuzosin may increase the hypotensive activities of Lercanidipine.Approved, Investigational
AliskirenLercanidipine may increase the hypotensive activities of Aliskiren.Approved, Investigational
AlprenololLercanidipine may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AmbrisentanLercanidipine may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmifostineLercanidipine may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Lercanidipine.Approved
AmiodaroneThe serum concentration of Lercanidipine can be increased when it is combined with Amiodarone.Approved, Investigational
AmlodipineAmlodipine may increase the hypotensive activities of Lercanidipine.Approved
AmobarbitalThe metabolism of Lercanidipine can be increased when combined with Amobarbital.Approved, Illicit
AmorolfineThe risk or severity of adverse effects can be increased when Amorolfine is combined with Lercanidipine.Approved
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Lercanidipine.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Amyl Nitrite is combined with Lercanidipine.Approved
AN2690The risk or severity of adverse effects can be increased when AN2690 is combined with Lercanidipine.Investigational
AnidulafunginThe risk or severity of adverse effects can be increased when Anidulafungin is combined with Lercanidipine.Approved, Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Lercanidipine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Apraclonidine is combined with Lercanidipine.Approved
AprepitantThe serum concentration of Lercanidipine can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Lercanidipine.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Lercanidipine.Approved
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Lercanidipine.Approved, Investigational
ArtemetherThe risk or severity of adverse effects can be increased when Artemether is combined with Lercanidipine.Approved
AtazanavirThe serum concentration of Lercanidipine can be increased when it is combined with Atazanavir.Approved, Investigational
AtenololAtenolol may increase the hypotensive activities of Lercanidipine.Approved
AtomoxetineThe metabolism of Lercanidipine can be decreased when combined with Atomoxetine.Approved
AtosibanThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Atosiban.Approved
Atracurium besylateLercanidipine may increase the neuromuscular blocking activities of Atracurium besylate.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Lercanidipine.Approved
Bafilomycin A1The risk or severity of adverse effects can be increased when Bafilomycin A1 is combined with Lercanidipine.Experimental
BarbexacloneBarbexaclone may increase the hypotensive activities of Lercanidipine.Experimental
BarbitalThe metabolism of Lercanidipine can be increased when combined with Barbital.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Lercanidipine.Approved
BenazeprilLercanidipine may increase the hypotensive activities of Benazepril.Approved, Investigational
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Lercanidipine.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Lercanidipine.Withdrawn
Benzoic AcidThe risk or severity of adverse effects can be increased when Benzoic Acid is combined with Lercanidipine.Approved
BepridilLercanidipine may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetaxololBetaxolol may increase the hypotensive activities of Lercanidipine.Approved
BethanidineBethanidine may increase the hypotensive activities of Lercanidipine.Approved
BexaroteneThe serum concentration of Lercanidipine can be decreased when it is combined with Bexarotene.Approved, Investigational
BifonazoleThe risk or severity of adverse effects can be increased when Bifonazole is combined with Lercanidipine.Approved
BimatoprostLercanidipine may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BisoprololLercanidipine may increase the hypotensive activities of Bisoprolol.Approved
BoceprevirThe serum concentration of Lercanidipine can be increased when it is combined with Boceprevir.Approved
BortezomibThe metabolism of Lercanidipine can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Lercanidipine can be decreased when it is combined with Bosentan.Approved, Investigational
BretyliumLercanidipine may increase the hypotensive activities of Bretylium.Approved
BrimonidineBrimonidine may increase the hypotensive activities of Lercanidipine.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Lercanidipine.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Lercanidipine.Approved, Investigational
BucindololBucindolol may increase the hypotensive activities of Lercanidipine.Investigational
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Lercanidipine.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Lercanidipine.Approved, Investigational
BupranololLercanidipine may increase the hypotensive activities of Bupranolol.Approved
ButenafineThe risk or severity of adverse effects can be increased when Butenafine is combined with Lercanidipine.Approved
ButoconazoleThe risk or severity of adverse effects can be increased when Butoconazole is combined with Lercanidipine.Approved
CalciumThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Calcium.Nutraceutical
Calcium AcetateThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Calcium Acetate.Approved
Calcium carbonateThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Calcium carbonate.Approved
Calcium ChlorideThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Calcium Chloride.Approved
Calcium citrateThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Calcium citrate.Approved
Calcium glubionateThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Calcium glubionate.Approved
Calcium GluceptateThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Calcium Gluceptate.Approved
Calcium gluconateThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Calcium gluconate.Approved, Vet Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Lercanidipine.Approved
CandesartanLercanidipine may increase the hypotensive activities of Candesartan.Approved
CandicidinThe risk or severity of adverse effects can be increased when Candicidin is combined with Lercanidipine.Withdrawn
CandoxatrilLercanidipine may increase the hypotensive activities of Candoxatril.Experimental
CaptoprilLercanidipine may increase the hypotensive activities of Captopril.Approved
CarbamazepineThe metabolism of Lercanidipine can be increased when combined with Carbamazepine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Lercanidipine.Approved
CarbomycinThe metabolism of Lercanidipine can be decreased when combined with Carbomycin.Vet Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Lercanidipine.Withdrawn
CarteololCarteolol may increase the hypotensive activities of Lercanidipine.Approved
CarvedilolLercanidipine may increase the hypotensive activities of Carvedilol.Approved, Investigational
CaspofunginThe risk or severity of adverse effects can be increased when Caspofungin is combined with Lercanidipine.Approved
CeliprololLercanidipine may increase the hypotensive activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Lercanidipine can be increased when it is combined with Ceritinib.Approved
CeruleninThe risk or severity of adverse effects can be increased when Cerulenin is combined with Lercanidipine.Approved
ChlorothiazideLercanidipine may increase the hypotensive activities of Chlorothiazide.Approved, Vet Approved
ChloroxineThe risk or severity of adverse effects can be increased when Chloroxine is combined with Lercanidipine.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Lercanidipine.Approved, Vet Approved
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Lercanidipine.Approved
CiclopiroxThe risk or severity of adverse effects can be increased when Ciclopirox is combined with Lercanidipine.Approved, Investigational
CilazaprilLercanidipine may increase the hypotensive activities of Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Lercanidipine.Approved
CimetidineThe serum concentration of Lercanidipine can be increased when it is combined with Cimetidine.Approved
ClarithromycinThe serum concentration of Lercanidipine can be increased when it is combined with Clarithromycin.Approved
ClemastineThe metabolism of Lercanidipine can be decreased when combined with Clemastine.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Clevidipine is combined with Lercanidipine.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Lercanidipine.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Lercanidipine.Approved, Vet Approved
ClonidineLercanidipine may increase the hypotensive activities of Clonidine.Approved
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Lercanidipine.Approved, Nutraceutical
ClotrimazoleThe risk or severity of adverse effects can be increased when Clotrimazole is combined with Lercanidipine.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Lercanidipine.Approved
CobicistatThe serum concentration of Lercanidipine can be increased when it is combined with Cobicistat.Approved
ConivaptanThe serum concentration of Lercanidipine can be increased when it is combined with Conivaptan.Approved, Investigational
CordycepinThe risk or severity of adverse effects can be increased when Cordycepin is combined with Lercanidipine.Investigational
CrizotinibThe metabolism of Lercanidipine can be decreased when combined with Crizotinib.Approved
CryptenamineLercanidipine may increase the hypotensive activities of Cryptenamine.Approved
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Lercanidipine.Approved, Investigational, Vet Approved
CyclosporineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Lercanidipine.Approved, Investigational, Vet Approved
CyclothiazideLercanidipine may increase the hypotensive activities of Cyclothiazide.Approved
DabrafenibThe serum concentration of Lercanidipine can be decreased when it is combined with Dabrafenib.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Dapagliflozin is combined with Lercanidipine.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Lercanidipine.Investigational
DarunavirThe serum concentration of Lercanidipine can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Lercanidipine can be increased when it is combined with Dasatinib.Approved, Investigational
DebrisoquinLercanidipine may increase the hypotensive activities of Debrisoquin.Approved
Decanoic AcidThe risk or severity of adverse effects can be increased when Decanoic Acid is combined with Lercanidipine.Experimental
DeferasiroxThe serum concentration of Lercanidipine can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Lercanidipine can be decreased when combined with Delavirdine.Approved
DeserpidineLercanidipine may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Lercanidipine.Approved
DexamethasoneThe serum concentration of Lercanidipine can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Lercanidipine.Approved, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Lercanidipine.Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Lercanidipine.Approved
DihydralazineLercanidipine may increase the hypotensive activities of Dihydralazine.Investigational
DihydroergotamineThe metabolism of Lercanidipine can be decreased when combined with Dihydroergotamine.Approved
DiltiazemThe metabolism of Lercanidipine can be decreased when combined with Diltiazem.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Lercanidipine.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Lercanidipine.Approved
DorzolamideLercanidipine may increase the hypotensive activities of Dorzolamide.Approved
DoxazosinLercanidipine may increase the hypotensive activities of Doxazosin.Approved
DoxycyclineThe metabolism of Lercanidipine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Lercanidipine can be decreased when combined with Dronedarone.Approved
DuloxetineLercanidipine may increase the orthostatic hypotensive activities of Duloxetine.Approved
EconazoleThe risk or severity of adverse effects can be increased when Econazole is combined with Lercanidipine.Approved
EfavirenzThe serum concentration of Lercanidipine can be decreased when it is combined with Efavirenz.Approved, Investigational
EfinaconazoleThe risk or severity of adverse effects can be increased when Efinaconazole is combined with Lercanidipine.Approved
EfonidipineLercanidipine may increase the hypotensive activities of Efonidipine.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Lercanidipine.Approved
EnalaprilLercanidipine may increase the hypotensive activities of Enalapril.Approved, Vet Approved
EnalaprilatLercanidipine may increase the hypotensive activities of Enalaprilat.Approved
EnzalutamideThe serum concentration of Lercanidipine can be decreased when it is combined with Enzalutamide.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Lercanidipine.Approved
EpoprostenolLercanidipine may increase the hypotensive activities of Epoprostenol.Approved
EprosartanLercanidipine may increase the hypotensive activities of Eprosartan.Approved
ErythromycinThe metabolism of Lercanidipine can be decreased when combined with Erythromycin.Approved, Vet Approved
Eslicarbazepine acetateThe serum concentration of Lercanidipine can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Lercanidipine.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Lercanidipine.Approved
EtravirineThe serum concentration of Lercanidipine can be decreased when it is combined with Etravirine.Approved
FelodipineLercanidipine may increase the hypotensive activities of Felodipine.Approved, Investigational
FenoldopamLercanidipine may increase the hypotensive activities of Fenoldopam.Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Lercanidipine.Approved
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Lercanidipine.Approved
FluconazoleThe serum concentration of Lercanidipine can be increased when it is combined with Fluconazole.Approved
FlucytosineThe risk or severity of adverse effects can be increased when Flucytosine is combined with Lercanidipine.Approved
FluvoxamineThe metabolism of Lercanidipine can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Lercanidipine can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Lercanidipine can be increased when it is combined with Fosaprepitant.Approved
FosinoprilFosinopril may increase the hypotensive activities of Lercanidipine.Approved
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Lercanidipine.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Lercanidipine.Approved, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Lercanidipine.Approved, Vet Approved
Fusidic AcidThe serum concentration of Lercanidipine can be increased when it is combined with Fusidic Acid.Approved
GlyphosateThe risk or severity of adverse effects can be increased when Glyphosate is combined with Lercanidipine.Experimental
GriseofulvinThe risk or severity of adverse effects can be increased when Griseofulvin is combined with Lercanidipine.Approved, Vet Approved
GuanabenzLercanidipine may increase the hypotensive activities of Guanabenz.Approved
GuanadrelGuanadrel may increase the hypotensive activities of Lercanidipine.Approved
GuanethidineLercanidipine may increase the hypotensive activities of Guanethidine.Approved
GuanfacineLercanidipine may increase the hypotensive activities of Guanfacine.Approved, Investigational
HaloproginThe risk or severity of adverse effects can be increased when Haloprogin is combined with Lercanidipine.Approved, Withdrawn
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Lercanidipine.Approved, Vet Approved
HexamethoniumLercanidipine may increase the hypotensive activities of Hexamethonium.Experimental
HexetidineThe risk or severity of adverse effects can be increased when Hexetidine is combined with Lercanidipine.Approved
HexobarbitalThe metabolism of Lercanidipine can be increased when combined with Hexobarbital.Approved
HydracarbazineHydracarbazine may increase the hypotensive activities of Lercanidipine.Approved
HydralazineLercanidipine may increase the hypotensive activities of Hydralazine.Approved
HydrochlorothiazideLercanidipine may increase the hypotensive activities of Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideLercanidipine may increase the hypotensive activities of Hydroflumethiazide.Approved
IdelalisibThe serum concentration of Lercanidipine can be increased when it is combined with Idelalisib.Approved
IloprostIloprost may increase the hypotensive activities of Lercanidipine.Approved, Investigational
ImatinibThe metabolism of Lercanidipine can be decreased when combined with Imatinib.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Lercanidipine.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Lercanidipine.Approved
IndapamideLercanidipine may increase the hypotensive activities of Indapamide.Approved
IndenololLercanidipine may increase the hypotensive activities of Indenolol.Withdrawn
IndinavirThe serum concentration of Lercanidipine can be increased when it is combined with Indinavir.Approved
IndoraminLercanidipine may increase the hypotensive activities of Indoramin.Withdrawn
IproclozideIproclozide may increase the hypotensive activities of Lercanidipine.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Lercanidipine.Withdrawn
IrbesartanLercanidipine may increase the hypotensive activities of Irbesartan.Approved, Investigational
IsavuconazoniumThe metabolism of Lercanidipine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Lercanidipine.Approved
IsoconazoleThe risk or severity of adverse effects can be increased when Isoconazole is combined with Lercanidipine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Lercanidipine.Approved, Vet Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Lercanidipine.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Lercanidipine.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Isoxsuprine is combined with Lercanidipine.Approved, Withdrawn
IsradipineThe metabolism of Lercanidipine can be decreased when combined with Isradipine.Approved
ItraconazoleThe serum concentration of Lercanidipine can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Lercanidipine can be increased when it is combined with Ivacaftor.Approved
JosamycinThe metabolism of Lercanidipine can be decreased when combined with Josamycin.Approved
KetanserinLercanidipine may increase the hypotensive activities of Ketanserin.Investigational
KetoconazoleThe serum concentration of Lercanidipine can be increased when it is combined with Ketoconazole.Approved, Investigational
KitasamycinThe metabolism of Lercanidipine can be decreased when combined with Kitasamycin.Experimental
LabetalolLercanidipine may increase the hypotensive activities of Labetalol.Approved
LacidipineLercanidipine may increase the hypotensive activities of Lacidipine.Approved
LatanoprostLercanidipine may increase the hypotensive activities of Latanoprost.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Levobunolol is combined with Lercanidipine.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Levobupivacaine.Approved
LevodopaLercanidipine may increase the orthostatic hypotensive activities of Levodopa.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Levosimendan.Approved, Investigational
LisinoprilLercanidipine may increase the hypotensive activities of Lisinopril.Approved, Investigational
LofexidineLercanidipine may increase the hypotensive activities of Lofexidine.Approved, Investigational
LopinavirThe serum concentration of Lercanidipine can be increased when it is combined with Lopinavir.Approved
LosartanLercanidipine may increase the hypotensive activities of Losartan.Approved
LovastatinThe metabolism of Lercanidipine can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Lercanidipine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Lercanidipine can be increased when combined with Lumacaftor.Approved
MacitentanLercanidipine may increase the hypotensive activities of Macitentan.Approved
Magnesium hydroxideThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Magnesium hydroxide.Approved
Magnesium oxideThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Magnesium oxide.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Magnesium salicylate.Approved
Magnesium SulfateThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Magnesium Sulfate.Approved, Vet Approved
ManidipineLercanidipine may increase the hypotensive activities of Manidipine.Approved
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Lercanidipine.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of Lercanidipine.Withdrawn
MecamylamineLercanidipine may increase the hypotensive activities of Mecamylamine.Approved
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Lercanidipine.Approved
MethohexitalThe metabolism of Lercanidipine can be increased when combined with Methohexital.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Lercanidipine.Approved
MethyldopaLercanidipine may increase the hypotensive activities of Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Lercanidipine.Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Lercanidipine.Approved, Investigational
MethylphenobarbitalThe metabolism of Lercanidipine can be increased when combined with Methylphenobarbital.Approved
MetipranololLercanidipine may increase the hypotensive activities of Metipranolol.Approved
MetolazoneMetolazone may increase the hypotensive activities of Lercanidipine.Approved
MetoprololLercanidipine may increase the hypotensive activities of Metoprolol.Approved, Investigational
MetyrosineLercanidipine may increase the hypotensive activities of Metyrosine.Approved
MevastatinThe risk or severity of adverse effects can be increased when Mevastatin is combined with Lercanidipine.Experimental
MibefradilLercanidipine may increase the hypotensive activities of Mibefradil.Withdrawn
MicafunginThe risk or severity of adverse effects can be increased when Micafungin is combined with Lercanidipine.Approved, Investigational
MiconazoleThe risk or severity of adverse effects can be increased when Miconazole is combined with Lercanidipine.Approved, Investigational, Vet Approved
MifepristoneThe serum concentration of Lercanidipine can be increased when it is combined with Mifepristone.Approved, Investigational
MiltefosineThe risk or severity of adverse effects can be increased when Miltefosine is combined with Lercanidipine.Approved
MinaprineMinaprine may increase the hypotensive activities of Lercanidipine.Approved
MinoxidilMinoxidil may increase the hypotensive activities of Lercanidipine.Approved
MitotaneThe serum concentration of Lercanidipine can be decreased when it is combined with Mitotane.Approved
MivacuriumLercanidipine may increase the neuromuscular blocking activities of Mivacurium.Approved
MoclobemideMoclobemide may increase the hypotensive activities of Lercanidipine.Approved
ModafinilThe serum concentration of Lercanidipine can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilLercanidipine may increase the hypotensive activities of Moexipril.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Lercanidipine.Approved
MonensinThe risk or severity of adverse effects can be increased when Monensin is combined with Lercanidipine.Vet Approved
MorphineThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Morphine.Approved, Investigational
MoxonidineLercanidipine may increase the hypotensive activities of Moxonidine.Approved
MyxothiazolThe risk or severity of adverse effects can be increased when Myxothiazol is combined with Lercanidipine.Experimental
NabiloneThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Nabilone.Approved, Investigational
NadololLercanidipine may increase the hypotensive activities of Nadolol.Approved
NafcillinThe metabolism of Lercanidipine can be increased when combined with Nafcillin.Approved
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Lercanidipine.Approved
NaftopidilLercanidipine may increase the hypotensive activities of Naftopidil.Investigational
NatamycinThe risk or severity of adverse effects can be increased when Natamycin is combined with Lercanidipine.Approved
NebivololLercanidipine may increase the hypotensive activities of Nebivolol.Approved, Investigational
NefazodoneThe serum concentration of Lercanidipine can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Lercanidipine can be increased when it is combined with Nelfinavir.Approved
NesiritideThe risk or severity of adverse effects can be increased when Nesiritide is combined with Lercanidipine.Approved, Investigational
NetupitantThe serum concentration of Lercanidipine can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Lercanidipine can be increased when combined with Nevirapine.Approved
NialamideNialamide may increase the hypotensive activities of Lercanidipine.Withdrawn
NicardipineLercanidipine may increase the hypotensive activities of Nicardipine.Approved
NicorandilNicorandil may increase the hypotensive activities of Lercanidipine.Approved
NifedipineThe risk or severity of adverse effects can be increased when Nifedipine is combined with Lercanidipine.Approved
NiguldipineLercanidipine may increase the hypotensive activities of Niguldipine.Experimental
NilotinibThe metabolism of Lercanidipine can be decreased when combined with Nilotinib.Approved, Investigational
NilvadipineLercanidipine may increase the hypotensive activities of Nilvadipine.Approved
NimodipineNimodipine may increase the hypotensive activities of Lercanidipine.Approved
NisoldipineNisoldipine may increase the hypotensive activities of Lercanidipine.Approved
NitrendipineLercanidipine may increase the hypotensive activities of Nitrendipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Nitric Oxide.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Lercanidipine.Approved, Investigational
NitroprussideLercanidipine may increase the hypotensive activities of Nitroprusside.Approved
NitroxolineThe risk or severity of adverse effects can be increased when Nitroxoline is combined with Lercanidipine.Approved
NystatinThe risk or severity of adverse effects can be increased when Nystatin is combined with Lercanidipine.Approved, Vet Approved
ObinutuzumabLercanidipine may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Lercanidipine.Withdrawn
OlaparibThe metabolism of Lercanidipine can be decreased when combined with Olaparib.Approved
OleandomycinThe metabolism of Lercanidipine can be decreased when combined with Oleandomycin.Vet Approved
OlmesartanOlmesartan may increase the hypotensive activities of Lercanidipine.Approved, Investigational
OmapatrilatLercanidipine may increase the hypotensive activities of Omapatrilat.Investigational
OsimertinibThe serum concentration of Lercanidipine can be increased when it is combined with Osimertinib.Approved
OxiconazoleThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Lercanidipine.Approved
OxprenololLercanidipine may increase the hypotensive activities of Oxprenolol.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Paclitaxel.Approved, Vet Approved
pafuramidineThe risk or severity of adverse effects can be increased when pafuramidine is combined with Lercanidipine.Investigational
PalbociclibThe serum concentration of Lercanidipine can be increased when it is combined with Palbociclib.Approved
PapaverineThe risk or severity of adverse effects can be increased when Papaverine is combined with Lercanidipine.Approved
PargylinePargyline may increase the hypotensive activities of Lercanidipine.Approved
PenbutololLercanidipine may increase the hypotensive activities of Penbutolol.Approved, Investigational
PentamidineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Lercanidipine.Approved
PentobarbitalThe metabolism of Lercanidipine can be increased when combined with Pentobarbital.Approved, Vet Approved
PentoliniumLercanidipine may increase the hypotensive activities of Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Lercanidipine.Approved, Investigational
PerindoprilLercanidipine may increase the hypotensive activities of Perindopril.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Lercanidipine.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Lercanidipine.Withdrawn
PhenobarbitalThe metabolism of Lercanidipine can be increased when combined with Phenobarbital.Approved
PhenoxybenzamineLercanidipine may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Lercanidipine.Withdrawn
PhentolamineLercanidipine may increase the hypotensive activities of Phentolamine.Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Lercanidipine.Approved, Vet Approved
PinacidilLercanidipine may increase the hypotensive activities of Pinacidil.Withdrawn
PindololLercanidipine may increase the hypotensive activities of Pindolol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Pipamperone.Approved
PirlindolePirlindole may increase the hypotensive activities of Lercanidipine.Approved
PivhydrazinePivhydrazine may increase the hypotensive activities of Lercanidipine.Withdrawn
PolythiazideLercanidipine may increase the hypotensive activities of Polythiazide.Approved
PosaconazoleThe serum concentration of Lercanidipine can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Pramipexole.Approved, Investigational
PrazosinPrazosin may increase the hypotensive activities of Lercanidipine.Approved
PrimidoneThe metabolism of Lercanidipine can be increased when combined with Primidone.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Propofol.Approved, Investigational, Vet Approved
PropranololLercanidipine may increase the hypotensive activities of Propranolol.Approved, Investigational
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Lercanidipine.Approved
QuinaprilLercanidipine may increase the hypotensive activities of Quinapril.Approved, Investigational
QuinineQuinine may increase the hypotensive activities of Lercanidipine.Approved
RadicicolThe risk or severity of adverse effects can be increased when Radicicol is combined with Lercanidipine.Experimental
RamiprilRamipril may increase the hypotensive activities of Lercanidipine.Approved
RanolazineThe metabolism of Lercanidipine can be decreased when combined with Ranolazine.Approved, Investigational
RapacuroniumLercanidipine may increase the neuromuscular blocking activities of Rapacuronium.Withdrawn
RasagilineRasagiline may increase the hypotensive activities of Lercanidipine.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Remifentanil.Approved
RemikirenRemikiren may increase the hypotensive activities of Lercanidipine.Approved
RescinnamineLercanidipine may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Lercanidipine.Approved
RifabutinThe metabolism of Lercanidipine can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Lercanidipine can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Lercanidipine can be increased when combined with Rifapentine.Approved
RilmenidineLercanidipine may increase the hypotensive activities of Rilmenidine.Investigational
RiociguatLercanidipine may increase the hypotensive activities of Riociguat.Approved
RisperidoneLercanidipine may increase the hypotensive activities of Risperidone.Approved, Investigational
RitonavirThe serum concentration of Lercanidipine can be increased when it is combined with Ritonavir.Approved, Investigational
RituximabLercanidipine may increase the hypotensive activities of Rituximab.Approved
RopiniroleThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Ropivacaine.Approved
RotigotineThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Rotigotine.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Sacubitril.Approved
SafrazineSafrazine may increase the hypotensive activities of Lercanidipine.Withdrawn
Salicylhydroxamic AcidThe risk or severity of adverse effects can be increased when Salicylhydroxamic Acid is combined with Lercanidipine.Experimental
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Lercanidipine.Approved, Vet Approved
SaprisartanLercanidipine may increase the hypotensive activities of Saprisartan.Experimental
SaquinavirThe serum concentration of Lercanidipine can be increased when it is combined with Saquinavir.Approved, Investigational
SecobarbitalThe metabolism of Lercanidipine can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Lercanidipine.Approved, Investigational, Vet Approved
SelexipagLercanidipine may increase the hypotensive activities of Selexipag.Approved
SertaconazoleThe risk or severity of adverse effects can be increased when Sertaconazole is combined with Lercanidipine.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Sevoflurane.Approved, Vet Approved
SildenafilSildenafil may increase the antihypertensive activities of Lercanidipine.Approved, Investigational
SilodosinSilodosin may increase the hypotensive activities of Lercanidipine.Approved
SiltuximabThe serum concentration of Lercanidipine can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Lercanidipine can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Lercanidipine.Approved
SinefunginThe risk or severity of adverse effects can be increased when Sinefungin is combined with Lercanidipine.Experimental
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Lercanidipine.Approved, Investigational
SitaxentanLercanidipine may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium NitriteThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Sodium Nitrite.Approved
SolithromycinThe metabolism of Lercanidipine can be decreased when combined with Solithromycin.Investigational
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Lercanidipine.Approved
SpiraprilLercanidipine may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Lercanidipine.Approved
St. John's WortThe serum concentration of Lercanidipine can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Lercanidipine can be increased when it is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Streptokinase.Approved
SufentanilThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Sufentanil.Approved, Investigational
SulconazoleThe risk or severity of adverse effects can be increased when Sulconazole is combined with Lercanidipine.Approved
SulfisoxazoleThe metabolism of Lercanidipine can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
TadalafilTadalafil may increase the antihypertensive activities of Lercanidipine.Approved, Investigational
TamsulosinTamsulosin may increase the hypotensive activities of Lercanidipine.Approved, Investigational
TavaboroleThe risk or severity of adverse effects can be increased when Tavaborole is combined with Lercanidipine.Approved
TelaprevirThe serum concentration of Lercanidipine can be increased when it is combined with Telaprevir.Approved
TelithromycinThe serum concentration of Lercanidipine can be increased when it is combined with Telithromycin.Approved
TelmisartanLercanidipine may increase the hypotensive activities of Telmisartan.Approved, Investigational
TemocaprilLercanidipine may increase the hypotensive activities of Temocapril.Experimental, Investigational
TerazosinTerazosin may increase the hypotensive activities of Lercanidipine.Approved
TerbinafineThe risk or severity of adverse effects can be increased when Terbinafine is combined with Lercanidipine.Approved, Investigational, Vet Approved
TerconazoleThe risk or severity of adverse effects can be increased when Terconazole is combined with Lercanidipine.Approved
TerlipressinLercanidipine may increase the hypotensive activities of Terlipressin.Approved, Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe metabolism of Lercanidipine can be increased when combined with Thiamylal.Approved, Vet Approved
ThiopentalThe metabolism of Lercanidipine can be increased when combined with Thiopental.Approved, Vet Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Lercanidipine.Approved
ThymolThe risk or severity of adverse effects can be increased when Thymol is combined with Lercanidipine.Approved
TiboloneLercanidipine may increase the hypotensive activities of Tibolone.Approved
TiclopidineThe metabolism of Lercanidipine can be decreased when combined with Ticlopidine.Approved
TicrynafenLercanidipine may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololTimolol may increase the hypotensive activities of Lercanidipine.Approved
TioconazoleThe risk or severity of adverse effects can be increased when Tioconazole is combined with Lercanidipine.Approved
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Lercanidipine.Approved
TocilizumabThe serum concentration of Lercanidipine can be decreased when it is combined with Tocilizumab.Approved
TolazolineLercanidipine may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Tolcapone.Approved, Withdrawn
TolnaftateThe risk or severity of adverse effects can be increased when Tolnaftate is combined with Lercanidipine.Approved, Vet Approved
ToloxatoneToloxatone may increase the hypotensive activities of Lercanidipine.Approved
TorasemideTorasemide may increase the hypotensive activities of Lercanidipine.Approved
TrandolaprilTrandolapril may increase the hypotensive activities of Lercanidipine.Approved
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Lercanidipine.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Lercanidipine.Approved
TravoprostTravoprost may increase the hypotensive activities of Lercanidipine.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Lercanidipine.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Lercanidipine.Approved
TrichlormethiazideLercanidipine may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrimazosinLercanidipine may increase the hypotensive activities of Trimazosin.Experimental
TrimethaphanLercanidipine may increase the hypotensive activities of Trimethaphan.Approved
TrimetrexateThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Lercanidipine.Approved, Investigational
TroleandomycinThe metabolism of Lercanidipine can be decreased when combined with Troleandomycin.Approved
TylosinThe metabolism of Lercanidipine can be decreased when combined with Tylosin.Vet Approved
UdenafilUdenafil may increase the antihypertensive activities of Lercanidipine.Approved, Investigational
UnoprostoneLercanidipine may increase the hypotensive activities of Unoprostone.Approved
ValsartanValsartan may increase the hypotensive activities of Lercanidipine.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Lercanidipine.Approved
VenlafaxineThe metabolism of Lercanidipine can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Lercanidipine can be decreased when combined with Verapamil.Approved
VinpocetineLercanidipine may increase the hypotensive activities of Vinpocetine.Investigational
VoriconazoleThe serum concentration of Lercanidipine can be increased when it is combined with Voriconazole.Approved, Investigational
XylometazolineLercanidipine may increase the hypotensive activities of Xylometazoline.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Lercanidipine.Approved, Vet Approved
ZiprasidoneThe metabolism of Lercanidipine can be decreased when combined with Ziprasidone.Approved
Food InteractionsNot Available
References
Synthesis Reference

Bandi Parthasaradhi Reddy, Kura Rathnakar Reddy, Rapolu Raji Reddy, Dasari Muralidhara Reddy, Dandamudi Satish Kumar, " NOVEL PROCESS FOR THE PREPARATION OF LERCANIDIPINE." U.S. Patent US20090227800, issued September 10, 2009.

US20090227800
General References
  1. Lin TH, Voon WC, Yen HW, Huang CH, Su HM, Lai WT, Sheu SH: Lercanidipine and losartan effects on blood pressure and fibrinolytic parameters. Kaohsiung J Med Sci. 2006 Apr;22(4):177-83. [PubMed:16679299 ]
  2. Martinez ML, Lopes LF, Coelho EB, Nobre F, Rocha JB, Gerlach RF, Tanus-Santos JE: Lercanidipine reduces matrix metalloproteinase-9 activity in patients with hypertension. J Cardiovasc Pharmacol. 2006 Jan;47(1):117-22. [PubMed:16424795 ]
  3. Agrawal R, Marx A, Haller H: Efficacy and safety of lercanidipine versus hydrochlorothiazide as add-on to enalapril in diabetic populations with uncontrolled hypertension. J Hypertens. 2006 Jan;24(1):185-92. [PubMed:16331117 ]
External Links
ATC CodesC09DB08C08CA13C09BB02
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9474
Blood Brain Barrier-0.9611
Caco-2 permeable-0.7039
P-glycoprotein substrateSubstrate0.9085
P-glycoprotein inhibitor IInhibitor0.9132
P-glycoprotein inhibitor IIInhibitor0.8957
Renal organic cation transporterNon-inhibitor0.7439
CYP450 2C9 substrateNon-substrate0.8448
CYP450 2D6 substrateNon-substrate0.8924
CYP450 3A4 substrateSubstrate0.7579
CYP450 1A2 substrateInhibitor0.6321
CYP450 2C9 inhibitorInhibitor0.7247
CYP450 2D6 inhibitorInhibitor0.5933
CYP450 2C19 inhibitorInhibitor0.7625
CYP450 3A4 inhibitorInhibitor0.5715
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7709
Ames testNon AMES toxic0.5517
CarcinogenicityNon-carcinogens0.668
BiodegradationNot ready biodegradable0.9895
Rat acute toxicity2.8614 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.5761
hERG inhibition (predictor II)Non-inhibitor0.6908
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP6.4Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.000156 mg/mLALOGPS
logP6.42ALOGPS
logP6.41ChemAxon
logS-6.6ALOGPS
pKa (Strongest Basic)9.36ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area113.69 Å2ChemAxon
Rotatable Bond Count14ChemAxon
Refractivity177.85 m3·mol-1ChemAxon
Polarizability65.78 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassDiphenylmethanes
Direct ParentDiphenylmethanes
Alternative Parents
Substituents
  • Diphenylmethane
  • Phenylpropylamine
  • Nitrobenzene
  • Dihydropyridinecarboxylic acid derivative
  • Aralkylamine
  • Dihydropyridine
  • Hydropyridine
  • Dicarboxylic acid or derivatives
  • Vinylogous amide
  • Alpha,beta-unsaturated carboxylic ester
  • Enoate ester
  • Methyl ester
  • Organic nitro compound
  • Tertiary aliphatic amine
  • Tertiary amine
  • Organic nitrite
  • C-nitro compound
  • Carboxylic acid ester
  • Azacycle
  • Organoheterocyclic compound
  • Organic 1,3-dipolar compound
  • Propargyl-type 1,3-dipolar organic compound
  • Allyl-type 1,3-dipolar organic compound
  • Organic oxoazanium
  • Enamine
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organic salt
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Organic zwitterion
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
This protein is a subunit of the dihydropyridine (DHP) sensitive calcium channel. Plays a role in excitation-contraction coupling. The skeletal muscle DHP-sensitive Ca(2+) channel may function only as a multiple subunit complex.
Gene Name:
CACNG1
Uniprot ID:
Q06432
Molecular Weight:
25028.105 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Burnier M, Pruijm M, Wuerzner G: Treatment of essential hypertension with calcium channel blockers: what is the place of lercanidipine? Expert Opin Drug Metab Toxicol. 2009 Aug;5(8):981-7. doi: 10.1517/17425250903085135. [PubMed:19619074 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23